Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | HBB | P68871 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | VCP | P55072 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | PNP | P00491 | 7/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | EDNRA | P25101 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valganciclovir SCHEMBL1120942 | 0.94 | PDE3A (0.85) | PDE3AMEN1KMT2AHBBMAPK1 | |
| Valganciclovir SCHEMBL15251689 | 0.93 | PDE3A (0.83) | PDE3AMEN1KMT2AHBBMAPK1 | |
| Valganciclovir SCHEMBL18837501 | 0.89 | PDE3A (0.77) | PDE3AMEN1KMT2AHBBMAPK1 | |
| Valganciclovir SCHEMBL28998 | 0.88 | PDE3A (1.00) | PDE3AMEN1KMT2AHBBMAPK1 | |
| (S)-Valganciclovir SCHEMBL28997 | 0.88 | PDE3A (0.74) | PDE3AMEN1KMT2AHBBMAPK1 | |
| (R)-Valganciclovir SCHEMBL13657988 | 0.88 | PDE3A (1.00) | PDE3AMEN1KMT2AHBBMAPK1 | |
| (R)-Valganciclovir SCHEMBL18040558 | 0.88 | PDE3A (1.00) | PDE3AMEN1KMT2AHBBMAPK1 | |
| Valganciclovir SCHEMBL28996 | 0.88 | PDE3A (0.74) | PDE3AMEN1KMT2AHBBMAPK1 | |
| (S)-Valganciclovir SCHEMBL22357189 | 0.88 | PDE3A (1.00) | PDE3AMEN1KMT2AHBBMAPK1 | |
| Valganciclovir SCHEMBL23225 | 0.88 | PDE3A (0.73) | PDE3AMEN1KMT2AHBBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10899824-B2 | Anti-HSV synergistic activity of antibodies and antiviral agents | POLICHEM S.A. (LU) | 2021-01-26 | — | — | US | disclosed |
| US-20190185546-A1 | ANTI-HSV SYNERGISTIC ACTIVITY OF ANTIBODIES AND ANTIVIRAL AGENTS | POLICHEM S.A. (LU) | 2019-06-20 | — | — | US | disclosed |
| EP-3491019-A1 | ANTI-HSV SYNERGISTIC ACTIVITY OF ANTIBODIES AND ANTIVIRAL AGENTS | Polichem S.A. (LU) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018019897-A1 | ANTI-HSV SYNERGISTIC ACTIVITY OF ANTIBODIES AND ANTIVIRAL AGENTS | POLICHEM S.A. (LU) | 2018-02-01 | — | — | WO | disclosed |
| US-20160000937-A1 | MODULATION OF TELOMERE LENGTH IN TELOMERASE POSITIVE CELLS AND CANCER THERAPY | ALT SOLUTIONS, INC. | 2016-01-07 | — | — | US | disclosed |
| US-9078901-B2 | Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer | ALT SOLUTIONS INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140113918-A1 | PHARMACOLOGICAL MODULATION OF TELOMERE LENGTH IN CANCER CELLS FOR PREVENTION AND TREATMENT OF CANCER | ALT SOLUTIONS INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140065072-A1 | Modulation of Telomere Length in Telomerase Positive Cells and Cancer Therapy | ALT SOLUTIONS INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-8609623-B2 | Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer | ALT SOLUTIONS INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8580753-B2 | Modulation of telomere length in telomerase positive cells and cancer therapy | ALT SOLUTIONS INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | ALT SOLUTIONS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090137503-A1 | Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer | ALT SOLUTIONS INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090023677-A1 | Modulation of Telomere Length in Telomerase Positive Cells and Cancer Therapy | ALT SOLUTIONS INC. | 2009-01-22 | — | — | US | disclosed |
| EP-2001488-A2 | PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES | Alt Solutions, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2006125166-A9 | PHARMACOLOGICAL MODULATION OF TELOMERE LENGTH IN CANCER CELLS FOR PREVENTION AND TREATMENT OF CANCER | ALT SOLUTIONS INC (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1885370-A2 | PHARMACOLOGICAL MODULATION OF TELOMERE LENGTH IN CANCER CELLS FOR PREVENTION AND TREATMENT OF CANCER | Alt Solutions, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1868615-A2 | MODULATION OF TELOMERE LENGTH IN TELOMERASE POSITIVE CELLS AND CANCER THERAPY | Alt Solutions, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007106561-A2 | PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES | ALT SOLUTIONS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2006125166-A2 | PHARMACOLOGICAL MODULATION OF TELOMERE LENGTH IN CANCER CELLS FOR PREVENTION AND TREATMENT OF CANCER | ALT SOLUTIONS, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006104975-A2 | MODULATION OF TELOMERE LENGTH IN TELOMERASE POSITIVE CELLS AND CANCER THERAPY | ALT SOLUTIONS, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | TERT, POLRMT, RNASE1 | PDE3A 2267/4885MEN1 2768/4885KMT2A 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.